Janis M. Petree, NP
Nurse Practitioner · Stanford
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
On the public record
- Medicare does not list them as allowed to order and refer
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Janis M. Petree’s office at (650) 498-6000 to ask if they take your plan before you enroll.
Drugs they prescribed that Part D paid
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their 15 Part D prescriptions in 2021. Too few prescriptions to judge: with under about 50 a year, a handful of patients can swing this share.
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Year by year
| 2021 | 15 | 11 | 0% (0) | None | $347 |
| 2020 | 15 | None | None | None | $531 |
| 2019 | 54 | 20 | None | None | $3,546 |
| 2018 | 35 | 22 | 0% (0) | None | $1,654 |
| 2017 | 83 | 42 | None | None | $8,382 |
| 2016 | 290 | 71 | 11% (32) | 13% | $179,588 |
| 2015 | 409 | 82 | 11% (45) | None | $158,592 |
| 2014 | 349 | 78 | 16% (54) | 9% | $51,916 |
| 2013 | 302 | 69 | 8% (23) | None | $70,249 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2019: 1 drug
| Anastrozole | 20 | $279 | $14 |
2017: 2 drugs
| Tamoxifen Citrate | 15 | $473 | $32 |
| Letrozole | 11 | $95 | $9 |
2016: 7 drugs
| Exemestane | 26 | $8,560 | $329 |
| Tamoxifen Citrate | 49 | $1,556 | $32 |
| Fentanyl | 11 | $1,178 | $107 |
| Hydrocodone-Acetaminophen | 13 | $816 | $63 |
| Anastrozole | 55 | $752 | $14 |
| Letrozole | 29 | $362 | $12 |
| Ondansetron | 13 | $141 | $11 |
2015: 12 drugs
| Ibrance | 11 | $109,479 | $9,953 |
| Exemestane | 34 | $11,122 | $327 |
| Fentanyl | 18 | $2,781 | $155 |
| Tamoxifen Citrate | 56 | $1,880 | $34 |
| Anastrozole | 64 | $1,075 | $17 |
| Hydrocodone-Acetaminophen | 17 | $1,035 | $61 |
| Letrozole | 38 | $454 | $12 |
| Cyclobenzaprine | 13 | $420 | $32 |
| Gabapentin | 14 | $261 | $19 |
| Pravastatin | 11 | $171 | $16 |
| Lisinopril | 12 | $60 | $5 |
| Diazepam | 13 | $53 | $4 |
2014: 6 drugs
| Anastrozole | 71 | $2,166 | $31 |
| Tamoxifen Citrate | 62 | $1,648 | $27 |
| Hydrocodone-Acetaminophen | 22 | $953 | $43 |
| Letrozole | 27 | $512 | $19 |
| Cyclobenzaprine | 11 | $385 | $35 |
| Gabapentin | 13 | $131 | $10 |
2013: 5 drugs
| Anastrozole | 101 | $3,702 | $37 |
| Exemestane | 15 | $3,122 | $208 |
| Letrozole | 27 | $981 | $36 |
| Tamoxifen Citrate | 45 | $970 | $22 |
| Megestrol Acetate | 17 | $804 | $47 |
Money from drug and device companies
$180 in 2022
| 2022 | 7 | 29 | None | $180 |
| 2021 | 21 | 70 | None | $873 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Eisai | Lenvima | $42 | 2 payments
|
| Seagen | Padcev | $27 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $25 | 1 payment
|
| Amgen | Lumakras | $22 | 1 payment
|
| GlaxoSmithKline | Blenrep | $22 | 1 payment
|
| Janssen Biotech | Imbruvica | $21 | 1 payment
|
See all 8 published payments
| Seagen | Meals · 2022-09-06 | Padcev | $27 |
| Eisai | Meals · 2022-04-07 | Lenvima | $19 |
| MorphoSys US | Meals · 2022-03-29 | Monjuvi | $21 |
| Amgen | Meals · 2022-02-08 | Lumakras | $22 |
| Janssen Biotech | Meals · 2022-02-07 | Imbruvica | $21 |
| GlaxoSmithKline | Meals · 2022-02-01 | Blenrep | $22 |
| Eisai | Meals · 2022-01-13 | Lenvima | $24 |
| AstraZeneca Pharmaceuticals LP | Meals · 2022-01-06 | Enhertu | $25 |
See earlier years (2021)
2021: $873
| Celgene | None | $106 | 5 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $102 | 5 payments
|
| Janssen Biotech | Imbruvica | $69 | 4 payments
|
| Seagen | Padcev | $69 | 3 payments
|
| Pfizer | Inlyta | $54 | 3 payments
|
| AbbVie | Venclexta | $53 | 2 payments
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $45 | 2 payments
|
| Merck Sharp & Dohme | Keytruda | $44 | 2 payments
|
| Eisai | Lenvima | $42 | 2 payments
|
| Rigel Pharmaceuticals | Tavalisse | $42 | 2 payments
|
| Kyowa Kirin | Poteligeo | $41 | 2 payments
|
| Daiichi Sankyo | Injectafer | $35 | 2 payments
|
| Ipsen Biopharmaceuticals | Somatuline Depot | $27 | 1 payment
|
| Novartis Pharmaceuticals | None | $23 | 1 payment
|
| Amgen | None | $22 | 1 payment
|
| Astellas Pharma US | Padcev | $20 | 1 payment
|
| Lilly USA | Verzenio | $19 | 1 payment
|
| ADC Therapeutics America | None | $18 | 1 payment
|
| Taiho Oncology | Inqovi | $17 | 1 payment
|
| MorphoSys US | Monjuvi | $13 | 1 payment
|
| Gilead Sciences | None | $12 | 1 payment
|
Professional record
- NPI
- 1477689644
- Licence
- CA NP8821
More record details
- Sole proprietor
- No
- Taxonomy
- Nurse practitioner (363L00000X)
- Mailing address
- 1804 Embarcadero Rd, Ste 100, Palo Alto, CA, 94303
- NPI first listed
- 2007-02-24
- NPI last updated
- 2016-10-14
This is when the NPI record was last certified, not a medical board exam.